Tenofovir (all routes except local)

Small for gestational age (length)

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S5160
R13457		 Pintye, 2015 6-week z-scores for length-for-age (LAZ) < −2 SD during pregnancy (anytime or not specified) retrospective cohort exposed to other treatment, sick Adjustment: Yes Control group: zidovudine/lamivudine/nevirapine Exposed group: TDF/lamivudine-based Indication: HIV 1.03 [0.51;2.06] 19/51   39/104 58 51
ref
S5124
R13304		 Siberry, 2012 Short birth length (z-scores <−1.50 (< 6.7th percentile)) during pregnancy (anytime or not specified) cohort exposed to other treatment, sick Adjustment: Yes Control group: non-TDF (mix or unspecified regimens) Exposed group: TDF (mix or unspecified regimens) Indication: HIV 1.18 [0.66;2.10] 25/293   40/447 65 293
ref
S5121
R13271		 Vigano, 2011 Length at birth (< 10th percentile) during pregnancy (anytime or not specified) prospective cohort exposed to other treatment, sick Adjustment: No Control group: non-TDF (mix or unspecified regimens) Exposed group: TDF (mix or unspecified regimens) Indication: HIV 0.94 [0.32;2.71] C 9/33   10/35 19 33
ref
Total 3 studies 1.09 [0.72;1.64] 142 377
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Pintye, 2015Pintye, 2015 1.03[0.51; 2.06]585135%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Siberry, 2012Siberry, 2012 1.18[0.66; 2.10]6529350%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Vigano, 2011Vigano, 2011 0.94[0.32; 2.71]193315%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Total (3 studies) I2 = 0% 1.09[0.72; 1.64]1423770.25.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.09[0.72; 1.64]1423770%NAPintye, 2015 Siberry, 2012 Vigano, 2011 3 case control studiescase control studies 0 Type of controls exposed to other treatment, sickexposed to other treatment, sick 1.09[0.72; 1.64]1423770%NAPintye, 2015 Siberry, 2012 Vigano, 2011 3 Tags Adjustment   - No  - No 0.94[0.32; 2.71]1933 -NAVigano, 2011 1   - Yes  - Yes 1.12[0.72; 1.74]1233440%NAPintye, 2015 Siberry, 2012 2 Control group   - non-TDF (mix or unspecified regimens)  - non-TDF (mix or unspecified regimens) 1.12[0.67; 1.86]843260%NASiberry, 2012 Vigano, 2011 2   - zidovudine/lamivudine/nevirapine  - zidovudine/lamivudine/nevirapine 1.03[0.51; 2.07]5851 -NAPintye, 2015 1 Exposed group   - TDF (mix or unspecified regimens)  - TDF (mix or unspecified regimens) 1.12[0.67; 1.86]843260%NASiberry, 2012 Vigano, 2011 2   - TDF/lamivudine-based  - TDF/lamivudine-based 1.03[0.51; 2.07]5851 -NAPintye, 2015 1 Indication   - HIV  - HIV 1.09[0.72; 1.64]1423770%NAPintye, 2015 Siberry, 2012 Vigano, 2011 3 All studiesAll studies 1.09[0.72; 1.64]1423770%NAPintye, 2015 Siberry, 2012 Vigano, 2011 30.25.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls exposed to other treatment, sick controlsexposed to other treatment, sick controls 1.09[0.72; 1.64]1423770%NAPintye, 2015 Siberry, 2012 Vigano, 2011 30.510.01.0